AnaptysBio, Inc. (ANAB)
NASDAQ
Closed
Sep 18, 2026
Day's Range
53.7152 wk Range
13.10Overview - ANAB - AnaptysBio, Inc.
Key Statistics
Valuation
Enterprise Value
1.59B
P/E (Trailing)
‪-120.17‬
P/E (Forward)
‪10.54‬
PEG Ratio
‪-2.74‬
Price / Sales (TTM)
‪7.03‬
Price / Book
‪125.74‬
EV / EBITDA
‪38.63‬
Profitability
Profit Margin
‪-11.52%‬
Operating Margin
‪-135.53%‬
Return on Assets
‪6.78%‬
Return on Equity
‪-114.55%‬
Ownership
Shares Outstanding
29.03M
Float
19.78M
Short % of Shares Outstanding
‪40.68%‬
Held by Insiders
‪5.67%‬
Held by Institutions
‪106.15%‬
Price stats
Beta
‪0.40‬
50-Day Avg
‪56.33‬
200-Day Avg
‪47.72‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 86.64‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ANAB - AnaptysBio, Inc.
Peers - ANAB - AnaptysBio, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ANABNASDAQAnaptysBio, Inc.1.63BMarket Cap+74.16%52-week change-120.17P/E (Trailing)‪-11.52%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ANAB - AnaptysBio, Inc.
About
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
